Empatic (bupropion SR/zonisamide SR) / Currax - LARVOL DELTA

BuZonE: Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes (clinicaltrials.gov) - P3; N=50; Recruiting; Sponsor: Rose Research Center, LLC; Trial completion date: Dec 2020 ➔ Jun 2021; Trial primary completion date: Dec 2020 ➔ Jun 2021

Trial completion date • Trial primary completion date • Tobacco Cessation

Professional quality of life and burnout among medical physicists working in radiation oncology: The role of alexithymia and empathy. (PubMed, Phys Imaging Radiat Oncol) - "Empathy results in higher professional fulfilment. These results may be used to benchmark preventing strategies, including peer support, debriefing sessions, leadership initiatives and work-load limitation strategies."

HEOR • Journal • Oncology

The role of alexithymia and empathy on radiation therapists' professional quality of life. (PubMed, Tech Innov Patient Support Radiat Oncol) - "Empathy resulted in higher professional fulfillment together with collegaues' appreciation. These results may be used to benchmark preventing strategies and implement organization-direct and/or individual-directed interventions."

HEOR • Journal • Oncology

BuZonE: Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes (clinicaltrials.gov) - P3; N=50; Recruiting; Sponsor: Rose Research Center, LLC; Not yet recruiting ➔ Recruiting

Enrollment open • Tobacco Cessation

BuZonE: Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes (clinicaltrials.gov) - P3; N=50; Not yet recruiting; Sponsor: Rose Research Center, LLC

New P3 trial • Tobacco Cessation

"@Empatica Inc. received clearance from the @US_FDA for their seizure-alerting smart watch Embrace. Embrace was supported by the Epilepsy Foundation in the early stages of its development. Find out more: https://t.co/OWqCx3VOb7" (@IndianaEpilepsy)

Biosimilar • CNS Disorders • Epilepsy

Generalized Seizure Detection And Alerting In The EMU With The Empatica Embrace Watch And Smartphone-Based Alert System (clinicaltrials.gov) - P=N/A; N=100; Recruiting; Sponsor: Empatica, Inc.; Not yet recruiting ➔ Recruiting; Trial primary completion date: Oct 2017 ➔ Jan 2018

Enrollment open • Trial primary completion date • Biosimilar • CNS Disorders • Epilepsy

"@empatica #Embrace maybe the first seizure @US_FDA medical grade approved #SeizureWearable #NeuroWearable, certainly won’t be the last... @epilepsysociety @EpilepsyRUK @epilepsyaction @CureEpilepsy @SudepAction @EpilepsyFdn @youngepilepsy" (@SeanPreneur)

Biosimilar • CNS Disorders • Epilepsy

Orexigen: Annual Report 2013 (Orexigen) - Anticipated composition of matter and methods of use patent expiry in US for obesity in 2023

Anticipated patent expiry • Obesity

Orexigen: BIO CEO & Investor Conference (Orexigen) - "Observed Case Analysis, Phase 2b; Empatic Provides a Different Tool for the Treatment of Obesity"

P2b data • Obesity

Specific Patient Features Affect Antiepileptic Drug Therapy Decisions. Focus on Gender, Age, and Psychiatric Comorbidities. (PubMed, Curr Pharm Des) - "A careful evaluation of the patient variables analysed in the present review is useful to personalize and optimize AED therapy."

Clinical • Journal

Empowering Cancer Patients for Non-pharmacological Primary Prevention and Early Recognition of Cancer-Associated Venous Thromboembolism (VTE): The Empatic-CP Survey (MASCC-ISOO 2019) - "Patient education for recognizing potentially life-threatening symptoms related to cancer, anticancer therapies and cancer-associated complications such as VTE poorly covered in our setting. The implementation of strategic educational programmes aimed at increasing patient awareness about cancer-associated emergencies and VTE is an area requiring further research and development."

Clinical